Exec Director, Viral Vector Process Development

Overview In this role you will lead end-to-end viral vector development to support clinical and commercial programs, guiding cross-functional teams across Research, Technical Operations, and Product Development. You will balance deep scientific expertise with executive influence to build scalable LVV platforms and enable both ex vivo and in vivo applications. You will drive tech transfer, process optimization, and next‑generation capabilities to advance cancer therapies. This leadership position combines scientific rigor with strategic oversight in a matrixed environment. Compensation / Benefitssalary: $255,425.00 - $330,550.00bonus eligibilitystock-based long-term incentivespaid time offcomprehensive benefits packagemedical, dental, vision, life insurance ResponsibilitiesSet technical strategy for LVV platforms across clinical and commercial scales, including tech transfers and external partnershipsProvide deep LVV design expertise (construct architecture, promoter choice, transgene optimization)Lead viral vector process development (upstream and downstream) and manufacturing supportDrive scale-up and tech transfer to clinical and commercial sitesOversee LVV lifecycle management and manufacturing support capabilitiesImprove vector productivity, robustness, and cost of goodsAdvance in vivo viral vector development and platform innovations Key requirementsPhD with 15+ years (or MS with 18+ years) experienceextensive viral vector development and manufacturing support for cell/gene therapyexpertise in LVV and/or RVV systemsend-to-end experience from early development to commercializationexperience leading cell therapy programs (e.g., CAR-T)ability to lead in a highly matrixed, cross-functional environmentinfluence on portfolio and strategic drug development decisionsstrong executive presenceclear communication of complex technical conceptsinfluencing and negotiation across senior stakeholdersLVV design (construct architecture, promoters, transgene optimization)upstream/downstream viral vector processestech transfer to clinical/commercial manufacturing